DOCSLIB.ORG

Efavirenz As a Psychotropic Drug

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efavirenz As a Psychotropic Drug European Review for Medical and Pharmacological Sciences 2020; 24: 10729-10735 Efavirenz as a psychotropic drug N. ZAREIFOPOULOS1, M. LAGADINOU1, A. KARELA1, F. POULIASI1, I. ECONOMOU1, A. TSIGKOU2, D. VELISSARIS1,3 1Emergency Department, University Hospital of Patras, Patras, Greece 2Department of Architecture, University of Patras, Patras, Greece 3Department of Internal Medicine, University of Patras School of Medicine, Patras, Greece Abstract. – OBJECTIVE: Antiretroviral drugs Introduction are the mainstay of treatment for human immu- nodeficiency virus (HIV) infection. Lifelong high- Neuropsychiatric adverse effects are a common ly active antiretroviral therapy (HAART) is in- occurrence in daily clinical practice, and they are dicated to prevent disease progression to ac- quired immunodeficiency syndrome (AIDS). Efa- frequently observed even during treatment with virenz was a first-line component of HAART drugs that would not be expected to affect the ner- across the world for many years. The purpose vous system. Antimicrobial agents have been asso- of this article is to review the psychotropic prop- ciated with neuropsychiatric adverse effects which erties of efavirenz, which are the most import- may be severe, but this rarely affects prescribing ant adverse events associated with the drug and practices and guidelines1. This is to be expected as commonly result in treatment discontinuation. MATERIALS AND METHODS: A PubMed infectious diseases are life-threatening, whereas search was conducted using efavirenz as a the typically reversible psychotropic side effects search term, which returned 4655 results. Titles of antimicrobial agents are not; and the drugs in- and abstracts of articles were screened for rele- dicated are extremely effective, perhaps more so vance, and all relevant articles published in En- than any other class of drugs for its specific indi- glish were included in the narrative review. cations. In rare cases the risks associated with the RESULTS: Acute exposure to efavirenz may cause profound perceptual disturbances (de- neuropsychiatric adverse effects of treatment may lusions and hallucinations) whereas chron- outweigh the benefits leading to a specific practice ic exposure may be associated with abnormal becoming a subject of controversy, such as the use dreams and other sleep disturbances, anxi- of neuraminidase inhibitors for the treatment of ety, depressed mood and suicidality. It may al- influenza in children which is outright contrain- so be abused as a hallucinogen, especially 2 in individuals with a history of poly-substance dicated due to the risk of behavioral disturbances abuse. Recent research indicates that efavirenz and the use of mefloquine (which has been associ- directly affects monoaminergic neurotransmis- ated with irreversible psychiatric disturbances) for sion and may partially substitute for psyche- malaria prophylaxis3,4. delic drugs, such as lysergic acid diethylam- Drugs indicated for the treatment of human ide (LSD). Efavirenz acts as a serotonin 5-HT2A immunodeficiency virus (HIV) infection are gen- receptor antagonist, a serotonin-dopamine re- uptake inhibitor, an inhibitor of monoamine ox- erally not well tolerated with most patients expe- idase (MAO) and a vesicular monoamine trans- riencing adverse effects which may limit treat- porter 2 (VMAT2) inhibitor, which are mecha- ment adherence or lead to discontinuation. The nisms common with many psychotropic drugs. mainstay of treatment for HIV infection is the use Efavirenz interacts with many of the same mo- of highly active antiretroviral therapy (HAART), lecular targets as the empathogen methylendi- which consists of a combination of at least 3 dif- oxymethamphetamine (MDMA), but the effects of the 2 drugs may differ. ferent antiretroviral drugs of at least 2 different 5 CONCLUSIONS: The exact mechanism of ac- classes . It is recommended that treatment should tion of efavirenz as a psychotropic drug remains be continued indefinitely once initiated, as inter- unclear and future studies should focus on eval- mittent exposure to antiretroviral drugs increases uating whether prolonged exposure could lead the risk of resistance. As HIV infections is in- to irreversible side effects. variably fatal without treatment, neuropsychiatric Key Words: effects of antiretroviral drugs would be cause Efavirenz, HIV, HAART, Serotonin, MDMA. for alarm as they may lead to reduced treatment Corresponding Author: Nicholas Zareifopoulos, MD; e-mail: [email protected] 10729 N. Zareifopoulos, M. Lagadinou, A. Karela, F. Pouliasi, I. Economou, A. Tsigkou, D. Velissaris adherence, but there is no question as to whether which arise as a result of prolonged exposure. the benefits of therapy outweigh the risks. Efa- Efavirenz use has been associated with delusions, virenz, however, was a first line component of hallucinations and other symptoms of psycho- HAART throughout the world due to its efficacy sis, whereas sleep disturbances and alteration in and relatively low risk of life-threatening adverse mood are common complaints after prolonged reactions, and for this reason most HIV positive use6-8. The neuropsychiatric adverse effects of individuals have been exposed to it. The most efavirenz are extremely common, being observed common adverse effects of efavirenz are related in up to 50% of patients on an efavirenz-contain- to its psychotropic properties, the mechanism ing HAART regimen, although these are rarely for which is not clear yet, though it may bear serious enough to warrant emergency medical similarities to the mechanism of action of known attention or discontinuation of treatment. Though drugs of abuse. Apart from the substantial risk of efavirenz may be associated with increased sui- non-adherence and treatment discontinuation as- cidality due to its psychotropic effects, the use sociated with these effects, the fact that efavirenz of efavirenz containing HAART regimens is not is a psychotropic drug may have substantial eth- linked to an increased risk of suicide compared to ical implications, as prolonged exposure to it the use of antiretroviral therapy regimens which could lead to psychiatric disturbances which may do not contain the drug. Abnormal, vivid dreams not be reversible immediately upon treatment are a common side effect of efavirenz and may discontinuation. Furthermore, as efavirenz may be due to the recommendation to take the drug at be abused due to its hallucinogenic properties and night9. Individuals who experience nightmares as may be trafficked alongside other drugs of abuse, a result of treatment may benefit by taking their any insight into its mechanism of action may dose during the day. The side effects of efavirenz have forensic implications as well. The objective may be attenuated by concurrent use of cy- of this study is to evaluate the data regarding the proheptadine10,11, a first-generation antihistamine psychotropic properties of efavirenz and review which also functions as a non-selective serotonin its clinical implications. antagonist, an option which may be in some cases preferable to discontinuation. It should be noted that efavirenz is highly protein bound and crosses Materials and Methods the blood brain barrier readily, attaining cerebro- spinal fluid concentrations similar to its plasma This study was conceived as a narrative re- concentrations. The absolute concentrations are view, with the intention of summarizing what however misleading as the protein content of the is known regarding the psychotropic properties CSF is several orders of magnitude lower than of efavirenz and the clinical implications of this that of blood plasma, so the free efavirenz con- information. A PubMed search for the term efa- centration of the CSF may be much greater than virenz was conducted, which revealed the entire- the plasma concentration (100-1000 times greater ty of the literature on the drug (4655 articles). in fact)12. Furthermore, in animal experiments13 it An abstract and title screen was conducted to has been found to accumulate in brain tissue, as identify articles relevant to the subject of this measured post mortem in whole brain dialysate. review, which were subsequently studied in their For these reasons it is among the drugs of choice entirety. All relevant reviews and original in- for AIDS with prominent CNS manifestations, vestigations were to be included in the narrative and it would make sense to attribute its psycho- review, in order to enable a qualitative synthesis tropic properties to a direct effect on the CNS. of the available data and to investigate its clinical Recreational use of efavirenz has been report- implications. ed in South Africa, where drug users smoke efa- virenz in combination with marijuana and other drugs, in a concoction known as whoonga14. The Results intended effect of this practice is unclear, but it suggests that the neuropsychiatric effects of Clinical Observations on the efavirenz are not necessarily unpleasant and they Neuropsychiatric Effects of Efavirenz may even be desirable for certain individuals Efavirenz has been associated with numerous in the right setting. Efavirenz may have hallu- psychiatric adverse effects, some of which occur cinogenic properties which are sought by drug immediately upon treatment initiation and others users, but it is unclear whether it is used for this 10730 Efavirenz as a psychotropic drug purpose as a sole drug or if its recreational value receptors, and at similar concentrations also po- manifests only in combination
Load more

Recommended publications
  • <I>Efavirenz</I>, New Therapeutic Agents for AIDS
    CONFERENCE REPORTS 295 CHIMIA 1999. 53. NO.6 CONFERENCE REPORTS Chimia 53 (1999) 295-304 © Neue Schweizerische Chemische Gesellschaft ISSN 0009-4293 Second Swiss/German Meeting on Medicinal Chemistry Fruhjahrsversammlung 1999 der Neuen Schweizerischen Chemischen Gesellschaft (NSCG) 22./23. Marz 1999, Basel Vier Mini-Symposia uber Virologie, Multidrug Resistance, Immunologie und Gene Therapie Organisiert von der Sektion Medizinische Ghemie der NSGG, der Fachgruppe fUr Medizinische Chemie der GDGh und der Basler Chemischen Gesellschatt mit Unterstutzung der Pharmazeutischen Industrie. Report by the Research Team of G. Folkers' 'Correspondence: Prof. Dr. G. Folkers Department of Pharmacy Winterthurerstrasse 190 CH-8057Zi.irich E-Mail: [email protected] Discovery of Indinavir and Efavirenz, New Therapeutic Agents for AIDS Terry A. Lyle, Merck Research Laboratories, West Point, PA, USA For the treatment of HIV infection, two enzymes are of major interest: The HIV-l Protease (PR) and the Reverse- Tran- scriptase (RT). The HIV -Protease, an aspartic-acid pro- tease active as a dimer, is responsible for H 0 the cleavage of polypeptides assembled at o N~' the cell membrane. The inhibition of the Y I( ; N 1\ 0 = H protease-mediated cleavage of the viral "0 o o o precursor polyproteins results in the pro- duction of noninfectious progeny viral par- ticles. The development of lndinavir start- ed with screening a collection of renin inhibitors. A seven-amino-acid analog 1 1 which contains the hydroxyethylene tran- CONFERENCE REPORTS 296 CHIMIA 1999, 53. No.6 prevents the spread of the virus. Different nucleoside inhibitors like AZT, ddI, ddC, d4T and 3TC are already known, but new QH non-nucleoside inhibitors (NNRTI) are U'O developed to decrease the cytotoxicity and N : to improve the selectivity of the viral polymerases vs.
    [Show full text]
  • African Journal of Drug & Alcohol Studies, 14(1), 2015 Copyright
    African Journal of Drug & Alcohol Studies, 14(1), 2015 Copyright © 2015, CRISA Publications iDentifYing the coMPoSition of Street Drug NYAOPE usINg TwO Different MASS SPectroMeter MethoDS aye a. khine1, kebogile E. Mokwena2, Mempedi Huma2, lucy Fernandes2 1Department of Chemical Pathology, Medunsa/University of Limpopo, South Africa 2Department of Public Health, Medunsa/University of Limpopo, South Africa ABStrAct Criminalizaton of trading and using of street drug Nyaope has had challenges in South Africa due to controversies about its compositon. The high cost and complexity of its analysis using conventonal chromatography methods also limit the testng availability in most routne laboratories. A state of the Art method with simple specimen processing and faster turnaround tme at an afordable cost is urgently needed. To compare the ability of a new Time-of-Flight Mass Spectrometry with direct sample analysis (TOF-DSA MS) and Gas Chromatography Mass Spectrometry (GC-MS) methods in detectng the consttuents of Nyaope against turnaround tme and cost, in order to recommend a beter system for routne use. Cross-sectonal, qualitatve and descriptve pilot study on samples purchased from various sources of 12 townships in Northern Gauteng Province. The consttuents consistently detected in all samples were cafeine, drugs of abuse such as opiates, codeine, morphine, methyl-dioxy amphetamine (MDA) and heroin. Some samples contained antbiotcs (citrofex) and antretroviral drugs (zidovudine). Central nervous system (CNS) depressants such as phenobarbitone and benzodiazepines, benzitramide, moramide intermediates and thiofentanyl and stmulants such as Pipradol, and fenethyline were detected by the TOF-MS system. The usefulness of TOF-DSA MS was beter as a screening method while GC-MS provides specifcity and confrmatory detecton.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • An Exploration of the Association Between the Whoonga/Nyaope Drug And
    An Exploration of the Association between the Whoonga/Nyaope Drug and Criminality through the Eyes of Convicted Drug Offenders in Three Metropolitan Cities of the Republic of South Africa by Siyanda Brightman Ngcobo Submitted in fulfilment of the requirements for the degree DOCTOR OF PHILOSOPHY IN CRIMINOLOGY AND FORENSIC STUDIES in the Discipline of Criminology and Forensic Studies School of Applied Human Sciences College of Humanities UNIVERSITY OF KWAZULU-NATAL (UKZN) Supervisor: Professor Jéan Steyn January 2019 DECLARATION I, Siyanda Brightman Ngcobo, declare that 1. The research reported in this thesis, except where otherwise indicated, and is my original research. 2. This thesis has not been submitted for any degree or examination at any other university. 3. This thesis does not contain any other persons’ data, pictures, graphs or other information, unless specifically acknowledged as being sourced from other persons. 4. This thesis does not contain any other persons’ writing, unless specifically acknowledged as being sourced from other researchers. Where other written sources have been quoted, then: a. Their words have been re-written but the general information attributed to them was referenced. b. Where their exact words have been used, then their writing has been placed in italics and inside quotation marks, and referenced. 5. This thesis does not contain text, graphics or tables copied and pasted from the Internet, unless specifically acknowledged and the source being detailed in the thesis and in the References sections. ----------------------------------------------- Siyanda Brightman Ngcobo On the 18th day of March 2019 i DEDICATION I dedicate this research project to all the Police Officers in the world; the men and women who put their lives on the line so that others may live.
    [Show full text]
  • Sustiva, INN-Efavirenz
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT SUSTIVA 50 mg hard capsules SUSTIVA 100 mg hard capsules SUSTIVA 200 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUSTIVA 50 mg hard capsules Each hard capsule contains 50 mg of efavirenz. Excipient with known effect Each hard capsule contains 28.5 mg of lactose (as monohydrate). SUSTIVA 100 mg hard capsules Each hard capsule contains 100 mg of efavirenz. Excipient with known effect Each hard capsule contains 57.0 mg of lactose (as monohydrate). SUSTIVA 200 mg hard capsules Each hard capsule contains 200 mg of efavirenz. Excipient with known effect Each hard capsule contains 114.0 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule SUSTIVA 50 mg hard capsules Dark yellow and white, printed with "SUSTIVA" on the dark yellow cap and "50 mg" on the white body. SUSTIVA 100 mg hard capsules White, printed with "SUSTIVA" on the body and "100 mg" on the cap. SUSTIVA 200 mg hard capsules Dark yellow, printed with "SUSTIVA" on the body and "200 mg" on the cap. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV- 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. SUSTIVA has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI) containing regimens.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Efavirenz) Capsules and Tablets 3 Rx Only
    1 SUSTIVA® 2 (efavirenz) capsules and tablets 3 Rx only 4 DESCRIPTION 5 SUSTIVA® (efavirenz) is a human immunodeficiency virus type 1 (HIV-1) specific, non- 6 nucleoside, reverse transcriptase inhibitor (NNRTI). 7 Capsules: SUSTIVA is available as capsules for oral administration containing either 8 50 mg, 100 mg, or 200 mg of efavirenz and the following inactive ingredients: lactose 9 monohydrate, magnesium stearate, sodium lauryl sulfate, and sodium starch glycolate. 10 The capsule shell contains the following inactive ingredients and dyes: gelatin, sodium 11 lauryl sulfate, titanium dioxide, and/or yellow iron oxide. The capsule shells may also 12 contain silicon dioxide. The capsules are printed with ink containing carmine 40 blue, 13 FD&C Blue No. 2, and titanium dioxide. 14 Tablets: SUSTIVA is available as film-coated tablets for oral administration containing 15 600 mg of efavirenz and the following inactive ingredients: croscarmellose sodium, 16 hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline 17 cellulose, and sodium lauryl sulfate. The film coating contains Opadry® Yellow and 18 Opadry® Clear. The tablets are polished with carnauba wax and printed with purple ink, 19 Opacode® WB. 20 Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- 21 (trifluoromethyl)-2H-3,1-benzoxazin-2-one. 22 Its empirical formula is C14H9ClF3NO2 and its structural formula is: 1 of 45 Approved v2.0 F C 3 Cl O NO 23 H 24 Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. 25 It is practically insoluble in water (<10 µg/mL).
    [Show full text]
  • SUSTIVA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Embryo-Fetal Toxicity: Avoid administration in the first trimester of These highlights do not include all the information needed to use pregnancy as fetal harm may occur. (5.6, 8.1) SUSTIVA safely and effectively. See full prescribing information for • Hepatotoxicity: Monitor liver function tests before and during treatment in SUSTIVA. patients with underlying hepatic disease, including hepatitis B or C SUSTIVA (efavirenz) capsules for oral use coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of SUSTIVA (efavirenz) tablets for oral use hepatic failure, a few occurred in patients with no pre-existing hepatic Initial U.S. Approval: 1998 disease. (5.8, 6.1, 8.6) ---------------------------INDICATIONS AND USAGE---------------------------­ • Rash: Rash usually begins within 1-2 weeks after initiating therapy and SUSTIVA is a non-nucleoside reverse transcriptase inhibitor indicated in resolves within 4 weeks. Discontinue if severe rash develops. (5.7, 6.1, 17) combination with other antiretroviral agents for the treatment of human • Convulsions: Use caution in patients with a history of seizures. (5.9) immunodeficiency virus type 1 infection in adults and in pediatric patients at • Lipids: Total cholesterol and triglyceride elevations. Monitor before least 3 months old and weighing at least 3.5 kg. (1) therapy and periodically thereafter. (5.10) • Immune reconstitution syndrome: May necessitate further evaluation and -----------------------DOSAGE AND ADMINISTRATION----------------------­ treatment. (5.11) • SUSTIVA should be taken orally once daily on an empty stomach, • Redistribution/accumulation of body fat: Observed in patients receiving preferably at bedtime. (2) antiretroviral therapy. (5.12, 17) • Recommended adult dose: 600 mg.
    [Show full text]
  • Call for a Harm-Reduction Approach to Drug-Use Disorders in South Africa
    Safe treatment and treatment of safety: call for a harm-reduction approach to 19 drug-use disorders in South Africa Authors: Andrew Scheibei,ii Shaun Shellyi,iii Anna Versfeldi Simon Howelliv Monique Marksii he complex political, structural and socio-economic factors that influence drug Regulation of drug use use and corresponding responses have contributed to the increasing drug- has largely relied on the T related burden of disease in South Africa. As a result, the country’s healthcare system is called on to manage the consequences of a public-health problem that has criminal-justice system and no ‘good solutions’. the view that people who Internationally, regulation of drug use has largely relied on the criminal-justice system use drugs are ‘the problem’, and the view that people who use drugs are ‘the problem’, deserving of punishment or ‘rehabilitation’. Over the past 30 years, a number of well-resourced democratic deserving of punishment governments have acknowledged the failure of such methods. This has resulted in a or ‘rehabilitation’. Over more medicalised approach to dealing with drug use, one that views habitual drug use as a chronic disease in need of treatment. Some recent South African policy the past 30 years, a documents have called for such an approach. In practice, however, enforcement and number of well-resourced punishment remain the dominant response, with the country only paying lip service democratic governments have to the provision of harm-reduction programmes. In addition, little attention has been given to the socio-economic context that encompasses and contributes to drug use, acknowledged the failure of this despite evidence that the existing policy and practice framework has created such methods.
    [Show full text]
  • Psychotropic Drugs: Sedatives/Hypnotics, Antidepressants, and Antipsychotics
    PSYCHOTROPIC DRUGS: SEDATIVES/HYPNOTICS, ANTIDEPRESSANTS, AND ANTIPSYCHOTICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) SEDATIVES/HYPNOTICS xLorazepam, oxazepam, temazepam xAlprazolam, Potential for n Potential for p Potential for n bromazepam, benzodiazepine benzodiazepine benzodiazepine buspirone, clonazepam, estazolam, flurazepam, diazepam, nitrazepam, zolpidem, zopiclone xMidazolam, Potential for n Potential for p Potential for n triazolam benzodiazepine benzodiazepine benzodiazepine PSYCHOTROPICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir,
    [Show full text]
  • Download PDF Flyer
    REVIEWS IN PHARMACEUTICAL & BIOMEDICAL ANALYSIS Editors: Constantinos K. Zacharis and Paraskevas D. Tzanavaras eBooks End User License Agreement Please read this license agreement carefully before using this eBook. Your use of this eBook/chapter constitutes your agreement to the terms and conditions set forth in this License Agreement. Bentham Science Publishers agrees to grant the user of this eBook/chapter, a non-exclusive, nontransferable license to download and use this eBook/chapter under the following terms and conditions: 1. This eBook/chapter may be downloaded and used by one user on one computer. The user may make one back-up copy of this publication to avoid losing it. The user may not give copies of this publication to others, or make it available for others to copy or download. For a multi-user license contact [email protected] 2. All rights reserved: All content in this publication is copyrighted and Bentham Science Publishers own the copyright. You may not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit any of this publication’s content, in any form by any means, in whole or in part, without the prior written permission from Bentham Science Publishers. 3. The user may print one or more copies/pages of this eBook/chapter for their personal use. The user may not print pages from this eBook/chapter or the entire printed eBook/chapter for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained from the publisher for such requirements.
    [Show full text]
  • Disproportionality Analysis of Antiretrovirals
    Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, March 3–6 2014 Poster #761 Disproportionality Analysis of Antiretrovirals with Suicidality using FDA Adverse Event Reporting System (FAERS) Data Daniel Seekins Andrew Napoli1, John Coumbis2, Jennifer Wood2, Amit Soitkar2, Daniel Seekins1 Bristol-Myers Squibb, Plainsboro, NJ, USA 1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Bristol-Myers Squibb, Hopewell, NJ, USA Email: [email protected] INTRODUCTION Statistical Analysis Suicide Attempt CONSIDERATIONS n A disproportionality analysis was performed for the selected drug and selected AE using the MGPS method Efavirenz (n = 107) Antiretrovirals n Psychiatric events, including depression, suicidal ideation, suicide attempts, and completed Antidepressants Strengths suicide have been reported in patients receiving efavirenz since 19981 Etravirine (n = 4) n The disproportionality measure, Empirical Bayesian Geometric Mean (EBGM), and the EB05 n FAERS is a large, independent, public dataset containing real-world data that can enable corresponding 90% CI (EB05, EB95) were estimated Nevirapine (n = 41) EBGM n Recently, a pooled analysis of four AIDS Clinical Trials Group (ACTG) studies (A5095, A5142, EB95 identification of potential signals for rare AEs A5175, A5202), identified an increased rate of suicidality with efavirenz-containing regimens n The threshold score above which a drug-event disproportionality signal is likely to be present Atazanavir (n = 13) compared to efavirenz-free regimens: is an EB05
    [Show full text]